Dexmedetomidine Hydrochloride In vs Dexmedetomidine — Cost, Coverage & Plan Comparison

Pick the drugs you want to compare.

Up to 4 drugsCross-class or same-class

Start with the molecules your plan spends the most on. Most useful comparisons live within the same therapeutic class — switching across classes requires deeper clinical review.

Drug 1

Drug 2

Drug 3 (optional)

Drug 4 (optional)

Side by side, line by line.

Federal data onlyNo PBM pricing assumed

Compare across

11 dimensions

Central alpha-2 Adrenergic Agonist

Dexmedetomidine Hydrochloride In

Brand: Dexmedetomidine Hydrochloride

First FDA approval: 2019-08-27

Central alpha-2 Adrenergic Agonist

Dexmedetomidine

Brand: Dexmedetomidine Hydrochloride in Sodium Chloride

First FDA approval: 2004-11-30

Lowest NADACAcquisition cost floor across all NDCs

—Per unit

Average NADACAcross all dosage forms and strengths

—

Generic manufacturersActive ANDA holders — FDA Orange Book

00 total ANDAs filed

2449 total ANDAs filed

Annualized Part D spendCY2024 — CMS Part D Spending Dashboard

—Full year

$308999Full year

Part D claims (CY24)Total fills, all strengths

—— beneficiaries

9742 beneficiaries

Avg cost per claimCalculated: total spend ÷ total claims

—Per claim, all NDCs

$3,186Per claim, all NDCs

Part D plans surveyed2026 plan year — CMS Formulary file

329Across CMS plan year

Prior-authorization frictionPlan-NDC pairs requiring PA

—Zero PA friction

Step therapy appliedPlan-NDC pairs requiring step therapy

—None

FDA shortage statusLive cross-reference vs FDA Drug Shortage Database

NoneClear

Active shortageSee drug profile

Generic availableFDA Orange Book

NoBrand-only

Yes24 manufacturers